Logo (Np Logo)
Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-166
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 71288-166). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel – Pemetrexed For Injection, Usp 100 mg Carton (Pem Hansoh 100mg Carton Np V4)
This text appears to be a detailed description of a medication contained in single-dose vials intended for intravenous use. The medication is a cytotoxic agent with a concentration of 100mg per vial. Instructions include details on reconstitution, storage, administration, and caution regarding its toxicity. The product is associated with Meitheal Pharmaceuticals and NovaPlus™, with possible manufacturing locations in the US and China. Additional contact information is provided for reference and usage instructions.*
Principal Display Panel – Pemetrexed For Injection, Usp 100 mg Vial Label (Pem Hansoh 100mg Vial Np V2)
Principal Display Panel – Pemetrexed For Injection, Usp 500 mg Carton (Pem Hansoh 500mg Carton Np V4)
This is a pharmaceutical label for Pemetrexed for Injection USP 500 mg per vial. The medication is a cytotoxic agent and should be used for intravenous purposes only. The label provides instructions for reconstitution and storage temperature. The product is manufactured by a pharmaceutical company based in the USA. The text also mentions the nonpyrogenic and preservative-free nature of the solution.*
Principal Display Panel – Pemetrexed For Injection, Usp 500 mg Vial Label (Pem Hansoh 500mg Vial Np V2)
Figure 3 (Pem Hansoh Np Fig 3)
Not available.*
Figure 6 (Pem Hansoh Np Fig 6)
This text provides information about the survival probability of patients in a study, plotted against survival time in months. The data refers to two groups - "Pemeveies" and "Placebo". The number of patients at risk is shown for various time points, ranging from 0 to 325 patients. The table suggests a comparison of survival rates between the two groups over time.*
Figure 1 (Pem Hansoh Np Fig1)
Figure 2 (Pem Hansoh Np Fig2)
This appears to be a graph showing survival probabilities for different treatment regimens such as Pemetrexed+Cisplatin and Gemcitabine+Cisplatin over a certain period of time in months. The data includes survival times and corresponding percentages. Further details or analysis could be provided with a more accurate conversion.*
Figure 4 (Pem Hansoh Np Fig4)
Figure 5 (Pem Hansoh Np Fig5)
This appears to be data related to survival probability and survival time for two groups of patients: "Pematesed" (441 patients) and "Placebo" (222 patients). The table shows the number of patients at risk at different time points, as well as their survival time in months. The data suggests a comparison between the two groups in terms of survival outcomes.*
Figure 7 (Pem Hansoh Np Fig7)
This is a survival probability table showing the number of patients at risk over different time intervals for two groups: "Pemeexed" and "Placebo." The table includes survival time in months and the corresponding number of patients at risk at each time point. It appears that the data is organized for comparison and analysis of survival rates between the two groups.*
Figure 8 (Pem Hansoh Np Fig8)
This is a table showing Survival Probability and Survival Time (in months) for two different groups: Pemevexsd and Placebo. It provides the number of patients at risk for each time point.*
Figure 9 (Pem Hansoh Np Fig9)
Structural Formula (Pem Hansoh Np Struct V2)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
